Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
BRCA1
BRCA2
HBOC (hereditary breast and ovarian cancer)
genetic counselling
homologous recombination
ovarian cancer
somatic variants
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
01
2022
accepted:
17
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Tumour testing of the
Identifiants
pubmed: 35463374
doi: 10.3389/fonc.2022.857515
pmc: PMC9026437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
857515Informations de copyright
Copyright © 2022 Azzollini, Vingiani, Agnelli, Tamborini, Perrone, Conca, Capone, Busico, Peissel, Rosina, Ducceschi, Mantiero, Lopez, Raspagliesi, Niger, Duca, Damian, Proto, de Braud, Pruneri and Manoukian.
Déclaration de conflit d'intérêts
FB: Consultant Advisory Board: Roche, EMD Serono, NMS Nerviano Medical Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini. Speaker: BMS, Healthcare Research & Pharmacoepidemiology, Merck Group, ACCMED, Nadirex, MSD, Pfizer, Servier, Sanofi, Roche, AMGEN, Incyte, Dephaforum. Principal Investigator for Novartis, F.Hoffmann-LaRoche Ltd, BMS, Ignyta Operating INC, Merck Sharp & Dohme Spa, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., LOXO Oncology Incorporated, DAICHI SANKIO Dev. Limited, Basilea Pharmaceutica International AG, Janssen-Cilag International NV, Merck KGAA MN: Travel expenses from Celgene, speaker honorarium from Accademia della Medicina and consultant honoraria from EMD Serono, Basilea Pharmaceutica, Incyte and MSD Italia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2014 Feb 07;4:4026
pubmed: 24504028
Int J Mol Sci. 2021 Oct 10;22(20):
pubmed: 34681592
Pathologica. 2021 Aug;113(4):262-271
pubmed: 34463674
J Natl Cancer Inst. 2020 Feb 1;112(2):161-169
pubmed: 31076742
Ann Oncol. 2016 May;27(5):795-800
pubmed: 26787237
Am J Transl Res. 2020 Feb 15;12(2):612-617
pubmed: 32194909
Lancet Oncol. 2021 Dec;22(12):1721-1731
pubmed: 34715071
Eur J Intern Med. 2016 Jul;32:65-71
pubmed: 27062684
Biomed Res Int. 2014;2014:542541
pubmed: 25136594
JCO Precis Oncol. 2020 Jun 16;4:
pubmed: 32923884
ESMO Open. 2016 Nov 18;1(5):e000094
pubmed: 27933214
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Clin Cancer Res. 2016 Aug 15;22(16):4087-4094
pubmed: 27083775
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
JAMA Oncol. 2016 Jan;2(1):104-11
pubmed: 26556299
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634417
Ann Oncol. 2021 Jan;32(1):103-112
pubmed: 33091561
J Clin Pathol. 2021 Sep;74(9):596-603
pubmed: 32895300
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503154
Ann Oncol. 2019 Aug 1;30(8):1221-1231
pubmed: 31050713
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
Diagnostics (Basel). 2021 Mar 21;11(3):
pubmed: 33801055
Nat Commun. 2021 Feb 17;12(1):1078
pubmed: 33597508
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
J Oncol. 2020 Apr 25;2020:6421205
pubmed: 32377194
JNCI Cancer Spectr. 2020 Mar 05;4(3):pkaa018
pubmed: 32596633
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
J Mol Diagn. 2018 Sep;20(5):600-611
pubmed: 29936257
J Natl Compr Canc Netw. 2021 Jul 28;19(7):871-878
pubmed: 34340209
JNCI Cancer Spectr. 2019 Apr 19;3(2):pkz028
pubmed: 31360904
BMC Genomics. 2014 Jun 24;15:516
pubmed: 24962530
JAMA Oncol. 2021 Feb 01;7(2):230-237
pubmed: 33126242
Cell. 2017 Feb 9;168(4):584-599
pubmed: 28187282
JCO Precis Oncol. 2021 Nov 17;5:
pubmed: 34820595
Hum Mol Genet. 2012 Nov 1;21(21):4669-79
pubmed: 22843497
Biomed Res Int. 2016;2016:5623089
pubmed: 27656653
Genet Med. 2021 Nov;23(11):2105-2113
pubmed: 34257420
JAMA Netw Open. 2019 May 3;2(5):e194428
pubmed: 31125106
ESMO Open. 2020 Jun;5(3):e000682
pubmed: 32576609